- Home
- GOF vs IBRX Comparison
GOF vs IBRX Comparison
Compare GOF & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOF
- IBRX
- Stock Information
- Founded
- GOF 2006
- IBRX 2014
- Country
- GOF United States
- IBRX United States
- Employees
- GOF N/A
- IBRX N/A
- Industry
- GOF Finance/Investors Services
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GOF Finance
- IBRX Health Care
- Exchange
- GOF Nasdaq
- IBRX Nasdaq
- Market Cap
- GOF 2.2B
- IBRX 1.9B
- IPO Year
- GOF N/A
- IBRX N/A
- Fundamental
- Price
- GOF $15.39
- IBRX $3.21
- Analyst Decision
- GOF
- IBRX Strong Buy
- Analyst Count
- GOF 0
- IBRX 3
- Target Price
- GOF N/A
- IBRX $13.58
- AVG Volume (30 Days)
- GOF 789.2K
- IBRX 6.3M
- Earning Date
- GOF 01-01-0001
- IBRX 11-12-2024
- Dividend Yield
- GOF 15.42%
- IBRX N/A
- EPS Growth
- GOF N/A
- IBRX N/A
- EPS
- GOF N/A
- IBRX N/A
- Revenue
- GOF N/A
- IBRX $7,332,000.00
- Revenue This Year
- GOF N/A
- IBRX $2,515.60
- Revenue Next Year
- GOF N/A
- IBRX $766.19
- P/E Ratio
- GOF N/A
- IBRX N/A
- Revenue Growth
- GOF N/A
- IBRX 1218.71
- 52 Week Low
- GOF $10.96
- IBRX $2.28
- 52 Week High
- GOF $16.76
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- GOF 50.60
- IBRX 53.70
- Support Level
- GOF $15.15
- IBRX $2.82
- Resistance Level
- GOF $15.36
- IBRX $3.30
- Average True Range (ATR)
- GOF 0.14
- IBRX 0.26
- MACD
- GOF 0.03
- IBRX 0.15
- Stochastic Oscillator
- GOF 64.87
- IBRX 90.69
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.